resazurin has been researched along with 1-methyl-4-phenylpyridinium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mitsumoto, Y; Mori, A; Nakai, M; Watanabe, A | 1 |
| Andrade, PB; Guedes-Dias, P; Leitão-Rocha, A; Oliveira, JM; Pinho, BR; Quintas, C; Reis, SD; Santos, MM; Valentão, P | 1 |
2 other study(ies) available for resazurin and 1-methyl-4-phenylpyridinium
| Article | Year |
|---|---|
1-methyl-4-phenylpyridinium (MPP+) decreases mitochondrial oxidation-reduction (REDOX) activity and membrane potential (Deltapsi(m)) in rat striatum.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Benzimidazoles; Carbocyanines; Coloring Agents; Corpus Striatum; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Fluorometry; Male; Membrane Glycoproteins; Membrane Potentials; Membrane Transport Proteins; Mitochondria; Nerve Tissue Proteins; Oxazines; Oxidation-Reduction; Parkinsonian Disorders; Piperazines; Presynaptic Terminals; Rats; Rats, Wistar; Sodium Cyanide; Synaptosomes; Tyrosine 3-Monooxygenase; Xanthenes | 2003 |
Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Behavior, Animal; Benzamides; Diencephalon; Disease Models, Animal; Histone Deacetylase 1; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Indoles; Larva; Locomotion; Neurotoxins; Oxazines; Parkinson Disease, Secondary; Pyridines; RNA, Messenger; Tyrosine 3-Monooxygenase; Xanthenes; Zebrafish; Zebrafish Proteins | 2016 |